CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Call for Feedback: Rituximab to Treat Primary Membranous Nephropathy

Published on: February 13, 2020
Result type: News

A new project on Rituximab to Treat Primary Membranous Nephropathy is now available for feedback from all interested stakeholders.

Rituximab to Treat Primary Membranous Nephropathy

Call for Feedback: 2020-02-13
Feedback Due By: 2020-02-28
Consultation Document: Proposed Project Scope
Product Type: Health Technology Assessment

Submit Feedback